, Volume 76, Issue 12, pp 1191–1201 | Cite as

Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis

  • Emma D. Deeks
Adis Drug Evaluation


Lumacaftor/ivacaftor (Orkambi™) is a fixed-dose tablet containing a corrector (lumacaftor) and potentiator (ivacaftor) of the cystic fibrosis transmembrane conductance regulator (CFTR) and is the first therapy approved to treat the underlying cause of cystic fibrosis in patients (aged ≥12 years) homozygous for the most common CFTR mutation, F508del. Lumacaftor improves the processing of F508del CFTR and its transport to the cell surface, while ivacaftor increases the channel’s open probability and transport of chloride. In two 24-week trials in the approved patient population (TRAFFIC and TRANSPORT), lumacaftor 400 mg plus ivacaftor 250 mg, administered every 12 h in combination with standard therapy, was associated with an ≈3 % statistically significant improvement in lung function relative to placebo (as measured by the percent predicted forced expiratory volume in 1 s). Lumacaftor plus ivacaftor did not significantly improve respiratory symptoms, although reduced pulmonary exacerbations to a clinically meaningful extent and, in one trial (TRANSPORT), significantly improved body mass index (BMI). In an ongoing extension of these studies (PROGRESS), lumacaftor plus ivacaftor provided clinical benefit over a further 72 weeks of treatment. Lumacaftor plus ivacaftor had an acceptable tolerability profile, with the most common adverse events being respiratory or gastrointestinal in nature. Thus, lumacaftor/ivacaftor expands the treatment options available for patients with cystic fibrosis homozygous for the F508del-CFTR mutation, although its precise place in clinical practice remains to be determined.


Cystic Fibrosis Cystic Fibrosis Transmembrane Conductance Regulator Improve Lung Function Pulmonary Exacerbation Lung Function Decline 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



During the peer review process, the manufacturer of lumacaftor/ivacaftor was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with Ethical Standards


The preparation of this review was not supported by any external funding.

Conflict of interest

Emma Deeks is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.


  1. 1.
    Cystic Fibrosis Foundation. About cystic fibrosis—what is cystic fibrosis? 2016. Accessed 11 Mar 2016.
  2. 2.
    Bosch B, De Boeck K. Searching for a cure for cystic fibrosis. A 25-year quest in a nutshell. Eur J Pediatr. 2016;175(1):1–8.CrossRefPubMedGoogle Scholar
  3. 3.
    O’Sullivan BP, Freedman SD. Cystic fibrosis. Lancet. 2009;373(9678):1891–904.CrossRefPubMedGoogle Scholar
  4. 4.
    Galietta LJ. Managing the underlying cause of cystic fibrosis: a future role for potentiators and correctors. Paediatr Drugs. 2013;15(5):393–402.CrossRefPubMedGoogle Scholar
  5. 5.
    Griesenbach U, Alton EW. Recent advances in understanding and managing cystic fibrosis transmembrane conductance regulator dysfunction. F1000Prime Rep. 2015;7:64.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6. Classification of CFTR mutations. 2016. Accessed 19 May 2016.
  7. 7.
    Mayo Clinic. Disease and conditions: cystic fibrosis. 2016. Accessed 11 Mar 2016.
  8. 8.
    Flume PA, Van Devanter DR. State of progress in treating cystic fibrosis respiratory disease. BMC Med. 2012;10:88.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Smyth AR, Bell SC, Bojcin S, et al. European Cystic Fibrosis Society standards of care: best practice guidelines. J Cyst Fibros. 2014;13(Suppl 1):S23–42.CrossRefPubMedGoogle Scholar
  10. 10.
    Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013;187(7):680–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Cytsic Fibrosis News Today. Cystic fibrosis statistics. 2016. Accessed 11 Mar 2016.
  12. 12.
    Deeks ED. Ivacaftor: a review of its use in patients with cystic fibrosis. Drugs. 2013;73(14):1595–604.CrossRefPubMedGoogle Scholar
  13. 13.
    Van Goor F, Hadida S, Grootenhuis PD, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci U S A. 2009;106(44):18825–30.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    CFTR Science. Clinician’s guide to CFTR. CFTR mutations: 127 are known to be CF-causing. 2015. Accessed 14 Mar 2016.
  15. 15.
    Castellani C, Cuppens H, Macek M Jr, et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cyst Fibros. 2008;7(3):179–96.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Flume PA, Liou TG, Borowitz DS, et al. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest. 2012;142(3):718–24.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Clancy JP, Rowe SM, Accurso FJ, et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax. 2012;67(1):12–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Vertex Pharmaceuticals Incorporated. Orkambi™ (lumacaftor/ivacaftor) tablets, for oral use: US prescribing information. 2016. Accessed 1 Jul 2016.
  19. 19.
    Vertex Pharmaceuticals (Europe) Limited. Orkambi 200 mg/125 mg film-coated tablets: EU summary of product characteristics. 2016. Accessed 1 Jul 2016.
  20. 20.
    Farinha CM, Sousa M, Canato S, et al. Increased efficacy of VX-809 in different cellular systems results from an early stabilization effect of F508del-CFTR. Pharmacol Res Perspect. 2015;3(4):e00152.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Van Goor F, Hadida S, Grootenhuis PD, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci USA. 2011;108(46):18843–8.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Ren HY, Grove DE, De La Rosa O, et al. VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1. Mol Biol Cell. 2013;24(19):3016–24.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Kopeikin Z, Yuksek Z, Yang HY, et al. Combined effects of VX-770 and VX-809 on several functional abnormalities of F508del-CFTR channels. J Cyst Fibros. 2014;13(5):508–14.CrossRefPubMedGoogle Scholar
  24. 24.
    Boucher RC. Cystic fibrosis: a disease of vulnerability to airway surface dehydration. Trends Mol Med. 2007;13(6):231–40.CrossRefPubMedGoogle Scholar
  25. 25.
    Eckford PDW, Ramjeesingh M, Molinski S, et al. VX-809 and related corrector compounds exhibit secondary activity stabilizing active F508del-CFTR after its partial rescue to the cell surface. Chem Biol. 2014;21(5):666–78.CrossRefPubMedGoogle Scholar
  26. 26.
    European Medicines Agency. Assessment report: Kalydeco (ivacaftor). 2012. Accessed 17 Mar 2016.
  27. 27.
    Eckford PD, Li C, Ramjeesingh M, et al. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner. J Biol Chem. 2012;287(44):36639–49.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Yu H, Burton B, Huang CJ, et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibros. 2012;11(3):237–45.CrossRefPubMedGoogle Scholar
  29. 29.
    Van Goor F, Yu H, Burton B, et al. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J Cyst Fibros. 2014;13(1):29–36.CrossRefPubMedGoogle Scholar
  30. 30.
    Veit G, Avramescu RG, Perdomo D, et al. Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression. Sci Transl Med. 2014;6(246):246ra97.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Matthes E, Goepp J, Carlile GW, et al. Low free drug concentration prevents inhibition of F508del CFTR functional expression by the potentiator VX-770 (ivacaftor). Br J Pharmacol. 2016;173(3):459–70.CrossRefPubMedGoogle Scholar
  32. 32.
    Cholon DM, Quinney NL, Fulcher ML, et al. Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis. Sci Transl Med. 2014;6(246):246ra96.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Marigowda G, Liu F, Waltz D. Effect of bronchodilators in healthy individuals receiving lumacaftor in combination with ivacaftor [abstract no. 256 plus poster]. Pediatr Pulmonol. 2014;49(S38):S307.Google Scholar
  34. 34.
    Boyle MP, Bell SC, Konstan MW, et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med. 2014;2(7):527–38.CrossRefPubMedGoogle Scholar
  35. 35.
    Stanton BA, Coutermarsh B, Barnaby R, et al. Pseudomonas aeruginosa reduces VX-809 stimulated F508del-CFTR chloride secretion by airway epithelial cells. PLoS One. 2015;10(5):e0127742.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Robertson SM, Luo X, Dubey N, et al. Clinical drug-drug interaction assessment of ivacaftor as a potential inhibitor of cytochrome P450 and P-glycoprotein. J Clin Pharmacol. 2015;55(1):56–62.CrossRefPubMedGoogle Scholar
  37. 37.
    Wainwright CE, Elborn JS, Ramsey BW, et al. Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for phe508del CFTR. N Engl J Med. 2015;373(3):220–31 (plus supplementary appendix).CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Konstan MW, Ramsey B, Elborn S, et al. Safety and efficacy of treatment with lumacaftor in combination with ivacaftor in patients with CF homozygous for F508del-CFTR [abstract no. 211]. Pediatr Pulmonol. 2015;50(Suppl 41):269–70.Google Scholar
  39. 39.
    Konstan MW, McKone EF, Moss RB, et al. Evidence for reduced rate of lung function decline and sustained benefit with combination lumacaftor and ivacaftor (LUM/IVA) therapy in patients (pts) 12 years of age with cystic fibrosis (CF) homozygous for the F508del-CFTR mutation [poster no. 108]. In: 8th European Conference on Rare Diseases & Orphan Products; 2016.Google Scholar
  40. 40.
    McColley SA, Konstan MW, Ramsey BW, et al. Association between changes in percent predicted FEV1 and incidence of pulmonary exacerbations, including those requiring hospitalization and/or IV antibiotics, in patients with CF treated with lumacaftor in combination with ivacaftor [abstract no. 241]. Pediatr Pulmonol. 2015;50(Suppl 41):282.Google Scholar
  41. 41.
    De Boeck K, Elborn JS, Ramsey BW, et al. Efficacy and safety of lumacaftor + ivacaftor combination therapy in patients with CF homozygous for F508del-CFTR by FEV1 subgroups [abstract no. 245]. Pediatr Pulmonol. 2015;50(Suppl 41):283–4.Google Scholar
  42. 42.
    Seliger V, Bai Y, Volkova N, et al. Prevalence of cataracts in a population of cystic fibrosis patients homozygous for the F508del mutation [abstract no. 196]. J Cyst Fibros. 2015;14(Suppl 1):S108.CrossRefGoogle Scholar
  43. 43.
    Liou TG, Adler FR, Fitzsimmons SC, et al. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol. 2001;153(4):345–52.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Mayer M. Lumacaftor-ivacaftor (Orkambi) for cystic fibrosis: behind the ‘breakthrough’. Evid Based Med. 2016. doi: 10.1136/ebmed-2015-110325.Google Scholar
  45. 45.
    Jones AM, Barry PJ. Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm? Thorax. 2015;70(7):615–6.CrossRefPubMedGoogle Scholar
  46. 46.
    Phuan PW, Veit G, Tan J, et al. Synergy-based small-molecule screen using a human lung epithelial cell line yields DeltaF508-CFTR correctors that augment VX-809 maximal efficacy. Mol Pharmacol. 2014;86(1):42–51.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Sawicki GS, McKone EF, Pasta DJ, et al. Sustained benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data. Am J Respir Crit Care Med. 2015;192(7):836–42.CrossRefPubMedGoogle Scholar
  48. 48.
    Sawicki GS, McKone EF, Millar S, et al. Similar rates of lung function decline in patients with cystic fibrosis and the G551D or hmozygous F508DEL CFTR gene mutation [abstract no. 487]. In: North American Cystic Fibrosis Conference; 2015.Google Scholar
  49. 49.
    Rubin JL, Pelligra CG, Ward AJ, et al. Modeling the intermediate health outcomes of patients with CF who are homozygous for the F508DEL CFTR mutation treated with lumacaftor and ivacaftor combination therapy [abstract no. 236]. Pediatr Pulmonol. 2015;50(Suppl 41):280.Google Scholar
  50. 50.
    Rehman A, Baloch NU, Janahi IA. Correspondence: lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med. 2015;373(18):1783.CrossRefPubMedGoogle Scholar
  51. 51.
    Gulland A. Cystic fibrosis drug is not cost effective, says NICE. BMJ. 2016;353:i3409.CrossRefPubMedGoogle Scholar
  52. 52.
    Vertex. FDA approves Orkambi™ (lumacaftor/ivacaftor)—the first medicine to treat the underlying cause of cystic fibrosis for people ages 12 and older with two copies of the F508del mutation [media release]. 2015. Accessed 2 July 2015.
  53. 53.
    European Medicines Agency. Report of the workshop on endpoints for cystic fibrosis clinical trials. 2012. Accessed 16 Mar 2016.

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations